gst-hg141
Small moleculeexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started May 20, 2020 (NCT04386915)
Timeline
Indications
Mechanism of action
- Hepatitis B virusINHIBITOR
Hepatitis B virus inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07090759 | Phase 3 | Jul 24, 2025 | Government of China |
| NCT05637541 | Phase 2 | Nov 23, 2022 | Government of China |
| NCT04868981 | Phase 1 | May 31, 2021 | Fujian Cosunter Pharmaceutical Co. Ltd, Jinlin University |
| NCT04386915 | Phase 1 | May 20, 2020 | Fujian Cosunter Pharmaceutical Co. Ltd, Jilin University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fujian Cosunter Pharmaceutical Co. Ltd | For profit | 2 | 2 | 1 | 2020 |
| Government of China | Government | 2 | 2 | 2 | 2022 |
| Jilin University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Jinlin University | Academic/Hospital | 1 | 0 | 1 | 2021 |
4 organizations
Page 1 / 1